SABS icon

SAB Biotherapeutics

34 hedge funds and large institutions have $2.41M invested in SAB Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
34
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

1 +$319K
2 +$35.2K
3 +$17.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$8.95K
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.36K

Top Sellers

1 -$69.7K
2 -$43K
3 -$30K
4
VF
Virtu Financial
New York
-$21K
5
Two Sigma Investments
Two Sigma Investments
New York
-$20.8K
Name Holding Trade Value Shares
Change
Change in
Stake
1
$615K
2
$509K
3
$319K
4
$225K
5
$175K
6
$121K
7
$51.2K
8
$46K
9
$43.5K
10
$37K
11
$33.2K
12
$33K
13
$29.9K
14
$29.4K
15
$28K
16
$17.4K
17
$14.5K
18
$13.2K
19
$10.2K
20
$9.71K
21
$9.47K
22
$9.41K
23
$8.66K
24
$6.36K
25
$6.3K